Saturday, August 2, 2025 8/2/2025

Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury

Award Number: R44AI183961
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/14/2024
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury - ABSTRACT Exposure to even moderate levels (<3 Gy) of ionizing radiation can result in severe pancyotopenia, placing patients as wells as victims of accidental exposure at high risks for infection and uncontrolled hemorrhaging. Accidental exposure differs from radiation therapy in that biodosimetry (e.g., type of radiation, dose and dose rate) is often uncertain; consequently, the optimal treatment regimen to ameliorate the effects of radiation is not immediately evident. Therefore, victims of accidental ionizing radiation exposure would benefit from bridging therapies to traverse extended periods of neutropenia and thrombocytopenia until the optimal course of medical care can be determined. Ossium Health proposes to develop a bank of myeloid committed progenitors (MCP) from deceased donor bone marrow (BM). The strategy employs commercially available GMP- compliant, closed-system flow separation device to specifically select MCP from whole BM based on defining cell surface markers CD34+CD38+. The proposed Phase II studies build on our previously successful Phase I, demonstrating our ability to select highly pure MCP from whole BM from deceased organ donors. In this phase we will refine selection and expand the pool of donor BM that can be used. The cells will be validated in vitro and in vivo in an immunocompromised mouse hematopoietic-acute radiation syndrome model to demonstrate enhanced survival. The overall product of this research program will be a compelling preclinical package to justify definitive studies to support FDA approval under the Animal Rule for a novel radiation/nuclear mass casualty medical countermeasure bridging therapy. Commercial viability for both medical countermeasures and civilian uses is enhanced by the up to 5-fold lower cost for manufacturing compared to current technologies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	OSSIUM HEALTH, INC.	80 TEHAMA ST	SAN FRANCISCO	CA	94105	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	11/20/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $375,113 )
2024	2024	OSSIUM HEALTH, INC.	78 TEHAMA ST	SAN FRANCISCO	CA	94105	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	8/14/2024	NEW	$375,113
														Subtotal = $375,113

Grand Total All Awards = $375,113

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury

Award Number: R44AI183961

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/14/2024

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer